Atlas Venture Life Science Advisors, LLC Q2 2023 Filing

Filed August 11, 2023

Portfolio Value

$803.6B

Holdings

15

Report Date

Q2 2023

Filing Type

13F-HR

All Holdings (15 positions)

#StockSharesValue% PortfolioType
1
IRONDisc Medicine, Inc.
3,461,784$153.7B19.13%
2
KYMRKymera Therapeutics, Inc.
5,858,262$134.7B16.76%
3
DYNDyne Therapeutics, Inc.
9,885,449$111.2B13.84%
4
DAWNDay One Biopharmaceuticals, Inc.
7,608,394$90.8B11.31%
5
VIGLVigil Neuroscience, Inc.
5,836,874$54.9B6.83%
6
THRDThird Harmonic Bio, Inc.
10,907,859$52.5B6.53%
7
REPLReplimune Group, Inc.
2,098,300$48.7B6.06%
8
GBIOGBXGeneration Bio, Co.
8,279,484$45.5B5.67%
9
AVTEAerovate Therapeutics, Inc.
2,039,249$35.0B4.35%
10
Ikena Oncology, Inc.
5,018,178$32.9B4.10%
11
AKROAkero Therapeutics, Inc.
594,251$27.7B3.45%
12
XLOXilio Therapeutics, Inc.
2,759,344$7.2B0.90%
13
AvroBio, Inc.
4,541,381$4.3B0.54%
14
Magenta Therapeutics, Inc.
3,791,698$2.9B0.36%
15
SPROSpero Therapeutics, Inc.
1,013,438$1.5B0.18%